Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis

Nat Med. 2020 Aug;26(8):1309. doi: 10.1038/s41591-020-0978-1.

Authors

Priscilla K Brastianos¹, Eudocia Quant Lee², Justine V Cohen³, Sara M Tolaney², Nancy U Lin², Nancy Wang³, Ugonma Chukwueke², Michael D White³, Naema Nayyar³, Albert Kim³, Christopher Alvarez-Breckenridge³, Ian Krop², Maura Keeley Mahar³, Mia S Bertalan³, Brian Shaw³, Joana L Mora³, Nathaniel Goss³, Megha Subramanian³, Lakshmi Nayak², Jorg Dietrich³, Deborah A Forst³, Brian V Nahed³, Tracy T Batchelor³, Helen A Shih³, Elizabeth R Gerstner³, Beverly Moy³, Donald Lawrence³, Anita Giobbie-Hurder², Scott L Carter², Kevin Oh³, Daniel P Cahill^#³, Ryan J Sullivan^#³

Affiliations

¹ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu.
² Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
³ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

^# Contributed equally.

PMID: 32555425
DOI: 10.1038/s41591-020-0978-1

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Publication types

Published Erratum